You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • AB0274 Impact of Baseline Anti-Cyclic Citrullinated Peptide 2 Antibody Titre on Efficacy Outcomes Following Treatment with Subcutaneous Abatacept or Adalimumab: 2-Year Results from the Ample Trial

Article metrics

Article menu
Download PDFPDF
Abstracts Accepted for Publication
Rheumatoid arthritis - prognosis, predictors and outcome
AB0274 Impact of Baseline Anti-Cyclic Citrullinated Peptide 2 Antibody Titre on Efficacy Outcomes Following Treatment with Subcutaneous Abatacept or Adalimumab: 2-Year Results from the Ample Trial

 

Online download statistics by month:

Online download statistics by month: June 2015 to March 2024

AbstractFullPdf
Jun 20152605
Jul 2015805
Aug 20152905
Sep 20152003
Oct 2015301
Nov 20152906
Dec 2015602
Jan 2016801
Feb 20162403
Mar 20162502
Apr 20162001
May 20161904
Jun 20161407
Jul 20161004
Aug 20162005
Sep 20161104
Oct 20161905
Nov 2016802
Dec 20161601
Jan 20171001
Feb 2017300
Mar 2017600
Apr 2017702
May 20171100
Jun 20171000
Jul 20171802
Aug 2017600
Sep 2017400
Oct 20171602
Nov 2017400
Dec 2017200
Jan 2018600
Feb 2018800
Mar 20181200
Apr 20181401
May 2018800
Jun 20181000
Jul 20181600
Aug 2018600
Sep 2018600
Oct 20181000
Nov 2018800
Jan 2019600
Feb 2019602
Apr 2019800
May 2019901
Jul 2019200
Aug 2019200
Sep 2019300
Oct 2019600
Nov 2019200
Dec 2019100
Feb 2020200
Mar 2020200
Apr 2020200
May 2020200
Jun 2020400
Jul 2020600
Sep 20201600
Oct 2020400
Nov 2020602
Dec 2020200
Feb 2021200
Mar 20211201
Apr 2021200
May 2021200
Jun 2021106
Oct 2021600
Nov 2021600
Dec 2021900
Jan 2022500
Feb 20221000
Mar 2022401
Apr 2022200
May 20221000
Jun 2022501
Jul 20222000
Aug 20221100
Sep 2022400
Oct 2022400
Nov 2022300
Dec 2022800
Jan 2023900
Feb 2023300
Mar 2023400
May 2023900
Jun 2023200
Jul 2023300
Aug 2023300
Sep 2023500
Oct 2023200
Dec 20231900
Jan 2024300
Feb 2024900
Mar 20241000
Total814088